A detailed history of China Universal Asset Management Co., Ltd. transactions in Nautilus Biotechnology, Inc. stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 24,121 shares of NAUT stock, worth $59,337. This represents 0.01% of its overall portfolio holdings.

Number of Shares
24,121
Previous 14,717 63.9%
Holding current value
$59,337
Previous $34,000 100.0%
% of portfolio
0.01%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

BUY
$2.24 - $3.08 $21,064 - $28,964
9,404 Added 63.9%
24,121 $68,000
Q2 2024

Jul 19, 2024

SELL
$2.22 - $3.0 $20,776 - $28,077
-9,359 Reduced 38.87%
14,717 $34,000
Q1 2024

Apr 29, 2024

BUY
$2.41 - $3.18 $23,193 - $30,604
9,624 Added 66.59%
24,076 $71,000
Q4 2023

May 21, 2024

SELL
$2.34 - $3.39 $22,520 - $32,625
-9,624 Reduced 39.97%
14,452 $43,000
Q4 2023

Jan 23, 2024

BUY
$2.34 - $3.39 $26,320 - $38,130
11,248 Added 351.06%
14,452 $43,000
Q3 2023

May 21, 2024

BUY
$2.87 - $3.94 $4,497 - $6,173
1,567 Added 95.72%
3,204 $10,000
Q3 2023

Oct 30, 2023

BUY
$2.87 - $3.94 $4,497 - $6,173
1,567 Added 95.72%
3,204 $10,000
Q2 2023

May 21, 2024

SELL
$2.21 - $4.52 $121 - $248
-55 Reduced 3.25%
1,637 $6,000
Q2 2023

Jul 27, 2023

SELL
$2.21 - $4.52 $121 - $248
-55 Reduced 3.25%
1,637 $6,000
Q1 2023

May 21, 2024

BUY
$1.67 - $2.77 $709 - $1,177
425 Added 33.54%
1,692 $4,000
Q1 2023

Apr 27, 2023

BUY
$1.67 - $2.77 $709 - $1,177
425 Added 33.54%
1,692 $5,000
Q4 2022

May 21, 2024

SELL
$1.55 - $2.47 $35,353 - $56,338
-22,809 Reduced 94.74%
1,267 $2,000
Q4 2022

Jan 31, 2023

BUY
$1.55 - $2.47 $153 - $244
99 Added 8.48%
1,267 $2,000
Q3 2022

Oct 21, 2022

BUY
$1.96 - $3.13 $2,289 - $3,655
1,168 New
1,168 $2,000

Others Institutions Holding NAUT

About Nautilus Biotechnology, Inc.


  • Ticker NAUT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 124,663,000
  • Market Cap $307M
  • Description
  • Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was found...
More about NAUT
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.